Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Liabilities and Shareholders Equity: 2015-2025

Historic Liabilities and Shareholders Equity for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to $372.7 million.

  • Cartesian Therapeutics' Liabilities and Shareholders Equity fell 18.15% to $372.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 12.03%. This contributed to the annual value of $435.0 million for FY2024, which is 42.61% up from last year.
  • Cartesian Therapeutics' Liabilities and Shareholders Equity amounted to $372.7 million in Q3 2025, which was down 4.17% from $388.9 million recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Liabilities and Shareholders Equity peaked at $455.3 million during Q3 2024, and registered a low of $106.0 million during Q3 2023.
  • In the last 3 years, Cartesian Therapeutics' Liabilities and Shareholders Equity had a median value of $347.7 million in 2024 and averaged $312.8 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Liabilities and Shareholders Equity plummeted by 40.52% in 2023 and then surged by 329.41% in 2024.
  • Cartesian Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $159.9 million in 2021, then grew by 3.75% to $165.9 million in 2022, then soared by 83.89% to $305.1 million in 2023, then spiked by 42.61% to $435.0 million in 2024, then decreased by 18.15% to $372.7 million in 2025.
  • Its last three reported values are $372.7 million in Q3 2025, $388.9 million for Q2 2025, and $409.1 million during Q1 2025.